DiaGenic ASA, of Oslo, Norway, and Pfizer Inc., of New York, have signed an agreement for an explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.